These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Chloroacryloyl amides and alpha-methylenelactones from naltrexone, oxymorphone and fentanyl. Archer S; Michael J; Michael M; Simon EJ; Abdelhamid EM; Nelson WL; Koolpe GA Neuropeptides; 1985 Feb; 5(4-6):395-8. PubMed ID: 2582304 [TBL] [Abstract][Full Text] [Related]
26. A spirohydantoin derivative of oxymorphone: an agonist with delayed antagonist activity. Alexander GJ; Chatterjie N; Wisniewski HM Pharmacol Biochem Behav; 1989 Apr; 32(4):939-43. PubMed ID: 2477864 [TBL] [Abstract][Full Text] [Related]
27. Opioid receptor interactions and conformations of the 6 alpha and 6 beta epimers of oxymorphamine. Solid-state conformation of 6 alpha-oxymorphamine. Lever OW; Bhatia AV; Chang KJ J Med Chem; 1985 Nov; 28(11):1652-6. PubMed ID: 2415705 [TBL] [Abstract][Full Text] [Related]
28. Receptor binding and analgesic properties of oxymorphazone. Galetta S; Ling GS; Wolfin L; Pasternak GW Life Sci; 1982 Sep 20-27; 31(12-13):1389-92. PubMed ID: 6183551 [TBL] [Abstract][Full Text] [Related]
30. Preparation of [3H]-oxymorphazone and its binding to rat brain membranes. Borsodi A; Varga E; Toth G; Hosztafi S NIDA Res Monogr; 1986; 75():220-3. PubMed ID: 2448626 [TBL] [Abstract][Full Text] [Related]
31. Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine. Botros S; Lipkowski AW; Larson DL; Stark PA; Takemori AE; Portoghese PS J Med Chem; 1989 Sep; 32(9):2068-71. PubMed ID: 2475628 [TBL] [Abstract][Full Text] [Related]
32. Orientation of the oxygen atom at C-6 as a determinant of agonistic activity in the oxymorphone series. Ronai AZ; Foldes FF; Hahn EF; Fishman J J Pharmacol Exp Ther; 1977 Mar; 200(3):496-500. PubMed ID: 66306 [TBL] [Abstract][Full Text] [Related]
33. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value. Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of gastrointestinal transit by morphine and FK 33-824 in the rat and comparative narcotic antagonist properties of naloxone and its N-methyl quaternary analog. Manara L; Bianchi G; Fiocchi R; Notarnicola A; Peracchia F; Tavani A Life Sci; 1982 Sep 20-27; 31(12-13):1271-4. PubMed ID: 6183550 [TBL] [Abstract][Full Text] [Related]
36. Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents. Wilson HA; Pasternak GW; Snyder SH Nature; 1975 Feb; 253(5491):448-50. PubMed ID: 46111 [No Abstract] [Full Text] [Related]
37. Effects of oxymorphazone in frogs: long lasting antinociception in vivo, and apparently irreversible binding in vitro. Benyhe S; Hoffmann G; Varga E; Hosztafi S; Toth G; Borsodi A; Wollemann M Life Sci; 1989; 44(24):1847-57. PubMed ID: 2472540 [TBL] [Abstract][Full Text] [Related]
38. A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site. Rothman RB; Bowen WD; Herkenham M; Jacobson AE; Rice KC; Pert CB Mol Pharmacol; 1985 Mar; 27(3):399-409. PubMed ID: 2579319 [TBL] [Abstract][Full Text] [Related]
39. Synthesis and binding of 3H-oxymorphazone to rat brain membranes. Varga E; Toth G; Benyhe S; Hosztafi S; Borsodi A Life Sci; 1987 Apr; 40(16):1579-88. PubMed ID: 2436019 [TBL] [Abstract][Full Text] [Related]